191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs

Autor: Rugo, H.S., Cescon, D.W., Im, S-A., Yusof, M. Md, Araneda, C.E. Gallardo, Lipatov, O., Cruz, F., Barrios, C.H., Hegg, R., Martín, E. Holgado, Torregroza Otero, M.A., Turner, N., Árkosy, P.F., Tarnawski, R., Karantza, V., Pan, W., Guo, Z., Cortés, J.

Publikováno v: In ESMO Open May 2023 8(1) Supplement 4

9P Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study.

Autor: Salazar Soler, R.¹ (AUTHOR), Santos Vivas, C.² (AUTHOR), Macias, I.³ (AUTHOR), Yubero Esteban, A.⁴ (AUTHOR), Bassam, A.⁵ (AUTHOR), Gallego Plazas, J.⁶ (AUTHOR), Al-Farhat, Y.⁷ (AUTHOR), Cervantes, A.⁸ (AUTHOR), García Alfonso, P.⁹ (AUTHOR), Paez, D.¹⁰ (AUTHOR), Ruiz-Casado, A.¹¹ (AUTHOR), Lopez, C.¹² (AUTHOR), Árkosy, P.F.¹³ (AUTHOR), Furka, A.¹⁴ (AUTHOR), Rodriguez-Salas, N.¹⁵ (AUTHOR), Ramos Pascual, F.J.¹⁶ (AUTHOR), Cubillo Gracian, A.¹⁷ (AUTHOR), Hitre, E.¹⁸ (AUTHOR), Ferreiro Monteagudo, R.¹⁹ (AUTHOR), Salud Salvia, M.A.²⁰ (AUTHOR)

Publikováno v: Annals of Oncology. 2024 Supplement 1, Vol. 35, pS6-S6. 1p.